Sarcosine

Category
amino acid
Routes
Oral (PO)
Half-Life (t½)
PO: 1h
Formula
C3H7NO2
Molecular Weight
89.09 g/mol
PubChem CID
1088
Aliases
N-methylglycine, N-methylaminoacetic acid

Pharmacological Mechanism

Endogenous N-methylated glycine and an inhibitor of the type-1 glycine transporter (GlyT1). Blocking GlyT1 raises synaptic glycine at the obligatory co-agonist site of the NMDA receptor, so sarcosine acts as an indirect NMDA enhancer rather than as a direct agonist — the basis for its trial use against the NMDA-hypofunction component of schizophrenia, where it has shown improvement in processing speed alongside positive-symptom scores.

Half-Life & Elimination Curve (PO: 1h)

100%50%25%12.5%0%0h0×t½1h1×t½2h2×t½3h3×t½4h4×t½5h5×t½0×t½ (0h): 100% remaining1×t½ (1h): 50% remaining2×t½ (2h): 25% remaining3×t½ (3h): 12.5% remaining4×t½ (4h): 6.3% remaining5×t½ (5h): 3.1% remaining
Elimination (PO)
  • 0×t½0h100%
  • 1×t½1h50%
  • 2×t½2h25%
  • 3×t½3h12.5%
  • 4×t½4h6.3%
  • 5×t½5h3.1%
Elimination t½1h (PO)
Rate Constant (ke)0.693 h⁻¹
97% Washout (5×t½)5h

Dosing Guidelines

Target Organ Systems

Notes

PubChem CID 1088 (C3H7NO2). PK: Amiaz 2015 (PMID:25841105), 22 stabilized schizophrenia patients on add-on open-label sarcosine — verbatim "Sarcosine exhibited linear kinetics, with a Tmax and t½ of ~1½- 2½ hr and ~1hr, respectively." The half-life is the point value and is stored; the Tmax is a RANGE (1.5-2.5 h), so no ka is back-derived from it — a range interior is not a measurement. Dose range is that study's two arms, verbatim "5 patients received 2 gm/d, and 17 received 4gm/d". No volume or bioavailability is published for oral sarcosine; both default, and the record is counted by pk.defaulted-volume. Cognitive endpoint in the same paper: "Speed of processing (MCCB subscale) improved significantly (Z=-2.13; P=0.03)". Mechanism reference PMID:16611082 (GlyT1 and its inhibitors).

Chemical Structure & Identifiers

References